NC-LENOVO
Today, Lenovo ™ (HKSE: 992) (ADR: LNVGY) launches the Kind City project —a vision to change urban environments forever and create future cities built on kindness.
By championing empathy in society, the project strives to encourage stronger, more inclusive communities made possible through smarter technology, and restore kindness in places where citizens feel increasingly disconnected.
Lenovo’s Kind City is the biggest crowdsourced public ‘census’ to imagine and co-author a blueprint for a city of the future built on kindness. It’s mission? To bring a more empathetic future to life through insight from global research, a public invitation to participate, and an interactive podcast featuring city dwellers and some of the world’s brightest minds.
“We believe the Kind City project will be the blueprint for mapping a kinder and better future,” said John Gordon, President of Industry Solutions at Lenovo. “Technology can and will make the future kinder, more inclusive, and more equitable. In cities, this means providing smarter technology for all—across socio-economic or cultural backgrounds—including both devices and solutions.”
Kind Council Formation and Interactive Podcast
Bringing together leading thinkers and global experts in their fields, Lenovo’s Kind City is steered by a panel of world-renowned visionaries who make up the project’s “Kind Council.” This includes British-American fashion designer and philanthropist Tan France, 2020 TIME Kid of the Year and inventor Gitanjali Rao, Brazilian rapper Emicida, UK robotics scientist Dr. Peter Scott-Morgan, German futurologist Oona Strathern, and Japanese author and entrepreneur Ibun Hirahara.
The group has collaborated on a choose-your-own-path podcast to discuss the fundamentals in achieving a Kind City, such as inclusion, trust, sustainability, dreams, and opportunity.
As the backbone of the entire initiative, the innovative podcast also explores powerful conversations and incredible stories with voices less commonly heard in futurism. Listeners can navigate from multigenerational living in the USA, to climate change in China, to tech hubs in Brazilian favelas, to dream research in the UK and a kindness currency in Japan.
The insightful and interactive podcast encourages listeners to become part of the discussion while giving them the opportunity to navigate an audio journey personalised to their interests. More than 20 stories, discussions, and interviews were captured from across the globe, from the United States and Germany to Japan and Brazil.
The podcast features NGO and charity partners from around the world, showcasing their efforts to support city residents. Lenovo will work directly with these organizations over the coming months and identify the most impactful ways to collaborate, from workshops on technology solutions with Lenovo experts, to device donations and financial support.
Major New Research Uncovers the ‘Kindness Gap’
The Kind City project comes on the heels of fresh research conducted by Lenovo that dives deep into the lives of city dwellers and their perspectives on the quality of life in their current cities.
Surveying more than 5,000 city dwellers across five countries (Brazil, Germany, Japan, United Kingdom, United States), the study exposes the growing need for society to rethink how we live together in city centers post-pandemic.
Research revealed traditional organizations and government are falling short on prioritizing kindness, leaving it to local neighborhoods and communities to shoulder more than their share of the responsibility.
Ultimately a major ‘Kindness Gap’ exists globally in cities with 97% of all polled believing it is important their communities have kindness/empathy, but only 37% feeling their current city is a kind place to live or work.
While the study finds respondents have a somewhat positive impression of the quality of life where they live, they also draw a clear connection between greater kindness in their cities and many tangible benefits, for example, improved mental and physical health; feelings of inclusivity and pride; greater enjoyment and flexibility, that could unlock even happier lifestyles. A significant opportunity for improvement in the face of these challenges exists, including:
-
Most respondents (55%) believe the quality of life in their city is either not getting better or staying the same. In cities across the globe, majorities say that there is room for improvement in their general living and working conditions.
-
City residents have reservations about how much the officials that represent them consider kindness when making decisions for the city. Less than one in five (17%) believe their policymakers strongly consider kindness and empathy when it comes to their city.
- Most residents think technology will be a pivotal solution (83%) for promoting and employing kindness in their cities, most notably in Brazil (88%).
What the kindness gap presents is a real opening to the private sector to enable and empower greater kindness and empathy. More than ever, there’s an urgency to work toward a more equitable future—and we can use the power of technology to make this come to fruition.
Get Involved: Become a Kind City Citizen
The initiative is calling upon people from all walks of life, across every major city to voice their vision of what a kinder city should be.
Lenovo invites the general public to share their personal vision of an empathetic and inclusive community by becoming Kind City citizens, which they can do by simply completing the following statement: “The future of the Kind City will…” on Lenovo’s microsite housing the project KindCity.com .
All responses received through November 15 will be curated using AI and transformed into 10 founding principles. These will be shared across the world through a range of exciting installations and experiential initiatives. Lenovo will also reveal details of collaborations with the global NGOs featured in the podcast, with actions shaped by Kind City submissions and research.
About Lenovo
Lenovo (HKSE: 992) (ADR: LNVGY) is a US$60 billion revenue Fortune Global 500 company serving customers in 180 markets around the world. Focused on a bold vision to deliver smarter technology for all, we are developing world-changing technologies that power (through devices and infrastructure) and empower (through solutions, services and software) millions of customers every day and together create a more inclusive, trustworthy and sustainable digital society for everyone, everywhere. To find out more visit https://www.lenovo.com and read about the latest news via our StoryHub .
View source version on businesswire.com: https://www.businesswire.com/news/home/20211026005167/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
TreeFrog Therapeutics Announces Changes to Executive Committee With the Arrival of Mark Rothera as Chief Executive Officer & Board Member to Spearhead Next Phase of Growth16.12.2025 09:05:00 CET | Press release
TreeFrog Therapeutics, a French biotech focused on bringing regenerative medicine to millions through their proprietary cell technology, C-Stem™ is delighted to announce the appointment of skilled biotech leader, Mark Rothera, as Chief Executive Officer and Board member. He succeeds Frédéric Desdouits, who is stepping down after five years in the role. In the new leadership configuration, co-founders Kévin Alessandri and Maxime Feyeux will transition from daily operations to focus on their roles on the Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251215145193/en/ Mark Rothera, CEO TreeFrog Therapeutics Elsy Boglioli, Chair of the Board of TreeFrog Therapeutics, commented “On behalf of the Board, we are delighted to welcome Mark to TreeFrog. His 30+ years of biopharma leadership, including most recently, three biotech CEO roles in gene therapy and biologics, will be invaluable as we advance our Parkinson’s and liver
RoslinCT and Ayrmid Ltd. Announce Expansion of Strategic Partnership to Manufacture Omisirge® (omidubicel-onlv) for Second FDA-Approved Indication in Severe Aplastic Anemia (SAA)16.12.2025 09:00:00 CET | Press release
RoslinCT is performing technology transfer and will support commercial manufacture of Omisirge® for an additional indication following successful clinical trialsOmisirge® now FDA-approved for an expanded patient population in hematologyRoslinCT continues to support and advance multiple cell therapy projects at its Hopkinton, MA facility Ayrmid Ltd., the parent company of Gamida Cell Inc., a pioneering cell therapy company transforming cells into powerful therapeutics, and RoslinCT, a global leader in cell and gene therapy contract development and manufacturing, today announced the expansion of their strategic partnership to include the execution of a commercial supply agreement to support production of Omisirge® (omidubicel-onlv). Following positive clinical trial results, Omisirge® has received FDA approval for a second indication, broadening its use in the treatment of hematology patients. Under the commercial supply agreement, RoslinCT will complete technology transfer and support c
Echoworx Secures FSQS-Netherlands Certification, Strengthening Trust in Financial Data Protection16.12.2025 07:00:00 CET | Press release
Leading encryption provider deepens commitment to European financial sector with rigorous new supplier qualification, building on existing UK & Ireland certification. Echoworx, a global leader in email and data encryption, proudly announces it has achieved Financial Services Qualification System (FSQS) registered supplier status for the Netherlands. This certification powerfully demonstrates Echoworx’s commitment to the highest standards of security and compliance. This achievement expands on the company’s existing FSQS certification for the UK and Ireland, secured in 2020. By successfully completing the rigorous qualification for the Netherlands, Echoworx reinforces its alignment with the stringent demands of the European financial market. The FSQS system, managed by Hellios, provides a single, reliable standard for vetting third-party suppliers, streamlining procurement for major banks and financial institutions. Think of FSQS as a high-security passport for technology partners. It p
Nippon Electric Glass to Start World’s First Mass Production of Low-Carbon Pharmaceutical Glass Tubing Using an All-Electric Furnace16.12.2025 03:00:00 CET | Press release
Nippon Electric Glass Co., Ltd. (NEG)(TOKYO:5214), a global leader in specialty glass headquartered in Otsu, Japan, announced it will begin the world’s first mass production of pharmaceutical-grade glass tubing using an all-electric melting furnace. Commercial production is scheduled to start in December 2025 at its subsidiary in Selangor, Malaysia. This breakthrough introduces a new manufacturing model for pharmaceutical packaging. By combining NEG’s proprietary all-electric melting technology with renewable energy, CO2 emissions from glass tubing production can be reduced by up to 90%*1 compared with conventional fossil-fuel combustion furnaces. This positions NEG as a major supplier capable of delivering both high-performance borosilicate glass and a significantly lower carbon footprint, directly addressing global sustainability demands from pharmaceutical companies and regulators. NEG is a leading global supplier of arsenic-free, environmentally friendly borosilicate glass tubing f
Esco Aster Signs Exosome Clinical cGMP Manufacturing Contract With Shine-On Biomedical For A Novel First-In-Class HLA-G Targeting Exosome Drug Delivery Platform16.12.2025 02:00:00 CET | Press release
Esco Aster, a vertically integrated cell and derivatives CRDMO based at JTC LaunchPad Singapore, announced CMC manufacturing support for Shine-On Biomedical’s HLA-G targeted exosome program. Shine-On Biomedical sponsored Esco Aster in 2023 for cGMP services, starting with high-yield exosome development using Esco Aster’s cell line platform. The technical reports of process, analytical, and formulation development, exosome drug loading, GMP engineering runs, and stability studies supported Shine-On’s IND submission. The IND was cleared by the U.S. FDA in Q1 2025. Furthermore, Esco Aster is providing technical services for exploratory exosome loading feasibility studies per Shine-On’s instruction. Shine-On Biomedical is an emerging innovator in exosome-based drug delivery. ShineOn’s proprietary product, SOB100, a HLA-G targeted exosome drug delivery carrier, has passed the U.S. FDA IND review and ongoing Phase I study, making it as a first-in-class–potential HLA-G targeted exosome platfo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
